US Market

I-MAB (IMAB) Stock Price & Analysis


IMAB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.17 - $7.67
Previous Close$1.2
Average Volume (3M)601.98K
Market Cap
Enterprise ValueN/A
Total Cash (Recent Filing)¥3.34B
Total Debt (Recent Filing)¥10.87M
Price to Earnings (P/E)-0.3
Mar 27, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.46
Shares Outstanding82,991,269
10 Day Avg. Volume1,241,052
30 Day Avg. Volume601,976
Standard Deviation0.23
Financial Highlights & Ratios
Price to Book (P/B)0.04
Price to Sales (P/S)-0.45
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside1691.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was I-MAB’s price range in the past 12 months?
I-MAB lowest stock price was $1.17 and its highest was $7.67 in the past 12 months.
    What is I-MAB’s market cap?
    Currently, no data Available
    When is I-MAB’s upcoming earnings report date?
    I-MAB’s upcoming earnings report date is Mar 27, 2024 which is in 185 days.
      How were I-MAB’s earnings last quarter?
      I-MAB released its earnings results on Aug 17, 2023. The company reported -$0.556 earnings per share for the quarter, beating the consensus estimate of -$1.31 by $0.754.
        Is I-MAB overvalued?
        According to Wall Street analysts I-MAB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does I-MAB pay dividends?
          I-MAB does not currently pay dividends.
          What is I-MAB’s EPS estimate?
          I-MAB’s EPS estimate is -$0.65.
            How many shares outstanding does I-MAB have?
            I-MAB has 83,439,740 shares outstanding.
              What happened to I-MAB’s price movement after its last earnings report?
              I-MAB reported an EPS of -$0.556 in its last earnings report, beating expectations of -$1.31. Following the earnings report the stock price went down -2.954%.
                Which hedge fund is a major shareholder of I-MAB?
                Among the largest hedge funds holding I-MAB’s share is Caxton Associates LP. It holds I-MAB’s shares valued at 75K.


                  I-MAB Stock Smart Score

                  This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                  Learn more about TipRanks Smart Score

                  Company Description


                  I-Mab is a clinical stage biopharmaceutical company. It engages in discovering, developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zhang Zang on June 30, 2016 and is headquartered in Pudong, China.


                  Top 5 ETFs holding IMAB

                  Currently, no data available
                  Please return soon. This page is being updated.
                  Up to five ETFs with an Outperform Smart Score that hold IMAB. The ETFs are listed according to market value of IMAB within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Rocket Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis